Efficacy of an anti-cancer strategy targeting SET in canine osteosarcoma

Area of Science:

• * Canine Osteosarcoma Research
• * Molecular Oncology
• * Tumor Suppressor Mechanisms

Background:

• * Osteosarcoma (OSA) is the most common primary bone tumor in dogs.
• * Protein phosphatase 2A (PP2A) is a key tumor suppressor, and SET protein inhibits its activity.
• * SET's role in canine OSA (cOSA) was previously unknown, despite its association with other malignancies.

Purpose of the Study:

• * To investigate the role of SET in canine osteosarcoma (cOSA).
• * To evaluate the anti-cancer effects of SET inhibition and targeting drugs in cOSA cell lines.
• * To explore combination therapy strategies for cOSA.

Main Methods:

• * Utilized two cOSA cell lines: POS (primary) and HM-POS (metastatic).
• * Employed SET knockdown (KD) to assess its impact on cell proliferation and colony formation.
• * Analyzed the effects of SET KD on key signaling pathways (ERK1/2, mTOR, E2F1, NF-κB).
• * Tested the anti-cancer efficacy of the SET-targeting drug FTY720, alone and in combination with cisplatin.

Main Results:

• * SET knockdown slightly suppressed POS cell proliferation but effectively inhibited colony formation in both POS and HM-POS cells.
• * SET KD repressed ERK1/2, mTOR, E2F1, and NF-κB signaling in HM-POS cells, and ERK1/2 signaling in POS cells.
• * The SET-targeting drug FTY720 demonstrated anti-cancer effects in both cOSA cell lines.
• * FTY720 enhanced the anti-cancer activity of cisplatin in cOSA cells.

Conclusions:

• * SET plays a significant role in the proliferation and colony formation of canine osteosarcoma cells.
• * Targeting SET, potentially with drugs like FTY720, shows promise for cOSA treatment.
• * Combination therapy involving SET inhibitors and cisplatin presents a potent strategy for managing cOSA.